BR112016018056A2 - Formas cristalinas de dolutegravir sódico e processos para suas preparações - Google Patents

Formas cristalinas de dolutegravir sódico e processos para suas preparações

Info

Publication number
BR112016018056A2
BR112016018056A2 BR112016018056A BR112016018056A BR112016018056A2 BR 112016018056 A2 BR112016018056 A2 BR 112016018056A2 BR 112016018056 A BR112016018056 A BR 112016018056A BR 112016018056 A BR112016018056 A BR 112016018056A BR 112016018056 A2 BR112016018056 A2 BR 112016018056A2
Authority
BR
Brazil
Prior art keywords
processes
crystalline forms
preparations
dolutegravir sodium
sodium
Prior art date
Application number
BR112016018056A
Other languages
English (en)
Portuguese (pt)
Inventor
Rao Jetti Ramakoteswara
Beeravelly Satish
Murthy Nadella Madhu
Nandipati Haribabu
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of BR112016018056A2 publication Critical patent/BR112016018056A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112016018056A 2014-02-07 2015-02-04 Formas cristalinas de dolutegravir sódico e processos para suas preparações BR112016018056A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2015/050841 WO2015118460A1 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
IN455MU2014 IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-02-07 2015-02-04

Publications (1)

Publication Number Publication Date
BR112016018056A2 true BR112016018056A2 (pt) 2017-08-08

Family

ID=53777379

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018056A BR112016018056A2 (pt) 2014-02-07 2015-02-04 Formas cristalinas de dolutegravir sódico e processos para suas preparações

Country Status (7)

Country Link
US (1) US10087193B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP3102582A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2015215630B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112016018056A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2938103C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015118460A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956662A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
EP3337479B1 (en) * 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
WO2017046131A1 (en) * 2015-09-15 2017-03-23 Ratiopharm Gmbh Processes for preparing solid state forms of dolutegravir sodium
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
KR102722927B1 (ko) * 2017-06-30 2024-10-28 비이브 헬쓰케어 컴퍼니 조합물 및 이의 용도 및 치료
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
US12227518B2 (en) * 2019-02-05 2025-02-18 Msn Laboratories Private Limited, R&D Center Crystalline polymorphs of sodium (4R,12AS)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido [1′,2′:4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof
CN114213432B (zh) * 2021-12-31 2023-02-17 瑞孚信江苏药业股份有限公司 度鲁特韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245182B (zh) * 2008-12-11 2014-07-23 盐野义制药株式会社 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof

Also Published As

Publication number Publication date
AU2015215630B2 (en) 2018-08-16
CA2938103C (en) 2021-08-10
US10087193B2 (en) 2018-10-02
CA2938103A1 (en) 2015-08-13
EP3102582A1 (en) 2016-12-14
IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-25
US20160347766A1 (en) 2016-12-01
AU2015215630A1 (en) 2016-09-22
WO2015118460A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
BR112016018056A2 (pt) Formas cristalinas de dolutegravir sódico e processos para suas preparações
ECSP23088864A (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
BR112016029605A8 (pt) (2r, 5s, 13ar) -7,9-dioxo-10-((2,4,6-trifluorobenzil) carbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-octa-hidro-2, 5-metanopirido [1',2': 4,5] pirazino [2,1-b] [1,3] oxazepin-8-olato de sódio, seu uso e composição farmacêutica
SV2017005487A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
MA40236A (fr) Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide
CO2018000350A2 (es) Forma cristalina de la plinabulina monohidratada, composiciones que la comprenden y procedimientos de elaboración
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY35745A (es) Derivados sustituidos de fenilalanina
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
MX377004B (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.
HK40106666A (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide
HK1235402A1 (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 498/14

Ipc: C07D 498/14 (2006.01), C07B 63/00 (2006.01), A61P

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]